Repligen
Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.
| Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found. | |
Company type | Public |
|---|---|
| Nasdaq: RGEN S&P 400 Component | |
| ISIN | Script error: No such module "WikidataIB". |
| Industry | Script error: No such module "WikidataIB". |
| Predecessor | Script error: No such module "WikidataIB". |
| Incorporated | Script error: No such module "WikidataIB". |
| Founded | Script error: No such module "WikidataIB". |
| Founders | Script error: No such module "WikidataIB". |
| Defunct | Script error: No such module "WikidataIB". |
| Successor | Script error: No such module "WikidataIB". |
| Headquarters | Waltham, Massachusetts , United States |
Key people | Olivier Loeillot (president and CEO)[1] |
| Products | Materials used in the manufacture of biological drugs |
| Revenue | Script error: No such module "WikidataIB". |
| Script error: No such module "WikidataIB". | |
| Script error: No such module "WikidataIB". | |
| Total assets | Script error: No such module "WikidataIB". |
Number of employees | Script error: No such module "WikidataIB". |
| Parent | Script error: No such module "WikidataIB". |
| Website | repligen |
Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.[2]
History
Repligen was founded in 1981 by Alexander RichLua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found. and Paul Schimmel and was incorporated in Delaware. It has a headquarters and manufacturing facility in Waltham, Massachusetts.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.
In 2008, an agreement was struck to divest certain intellectual property rights to Bristol-Myers Squibb around the drug Orencia in exchange for ongoing royalty payments through the end of 2013.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.
In 2011, Repligen acquired bioproduction assets from Novozymes, which doubled the company's bioprocessing capabilities.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.
Before 2012, Repligen maintained dual capabilities in developing pharmaceutical therapeutics (drug discovery and development) and the development of materials supporting biological drug manufacture (bioprocessing business).Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found. A decision was made in 2012 to focus on the bioprocessing business and reduce research and development expenditures.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.
Development of an imaging agent, designated RG1068, based on a synthetic human hormone was halted in 2012 following a request by the USFDA for additional safety and efficacy data beyond that provided in a New Drug Application (NDA) submission; a Marketing Authorization Application had been submitted in parallel to the EMA.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.
At the end of 2012, Repligen out-licensed its spinal muscular atrophy program, in particular the small molecule candidate drug RG3039, to Pfizer.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found. This divestment included licensing rights to two patents to Pfizer.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.[3][4]
At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for Template:Currency and future milestone and royalty payments.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.
Repligen has made several acquisitions through the early 2020s, including BioFlex Solutions[5] and Tantti Laboratory Inc.[6] among others.[7][8]
As of 2024[update], the company's President and Chief Executive Officer is Olivier Loeillot.[9]
As of 2025 it employs approximately 2,000 employees across several sites in the United States, Europe, and Asia.[10]
Products and services
Repligen develops and manufactures products used in bioprocessing and biological drug manufacturing. The company was a major supplier of Protein A, both native and recombinant forms, to the pharmaceutical industry, which accounted for most of its sales in the early 2010s.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found. It has since expanded into other areas, including filtration and fluid management, chromatography, process analytics and proteins, serving biologics such as monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, mRNA products, and cell and gene therapies. Some of its better-known product families include XCell ATF perfusion systems,[11][12] OPUS pre-packed chromatography columns,[13][14] KrosFlo tangential flow filtration systems,[15][16] and CTech variable pathlength spectroscopy systems such as SoloVPE and FlowVPE.[17][18] Many of these expansions have occurred through acquisitions, including BioFlash (OPUS),Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found. Refine Technology (ATF),[19] ARTeSYN Biosolutions,[20] and others.[7]Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.
Growth factor products and the native form of Protein A and recombinant Protein A are manufactured in Sweden; assembly of the OPUS chromatography product line is done in the United States.Lua error in package.lua at line 80: module 'Module:Footnotes/anchor_id_list' not found.
References
Page Template:Reflist/styles.css has no content.
- ^ https://investors.repligen.com/press-releases/news-details/2024/Repligen-Announces-CEO-Transition-Plan/default.aspx
- ^ Nasdaq: RGEN
- ^ Page Template:Citation/styles.css has no content.US 7888366 "2,4-diaminoquinazolines for spinal muscular atrophy"
- ^ Page Template:Citation/styles.css has no content.US 7985755 "2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY"
- ^ Page Module:Citation/CS1/styles.css has no content."Repligen | Inspiring advances in bioprocessing". Repligen. Retrieved 2025-10-10.
- ^ Page Module:Citation/CS1/styles.css has no content."Repligen Announces Agreement to Acquire Chromatography Innovator Tantti". www.tantti.com. 2024-07-29. Retrieved 2025-10-10.
- ^ a b Page Module:Citation/CS1/styles.css has no content."Repligen (RGEN) to Acquire Fluid Management Company Metenova". Nasdaq.com. September 27, 2023.
- ^ Page Module:Citation/CS1/styles.css has no content."Repligen lays down $70m to buy PAT tools from 908 Devices". BioProcess International. Retrieved 2025-10-10.
- ^ Page Module:Citation/CS1/styles.css has no content."Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance" (PDF). Repligen. 2026-05-05. Archived from the original (PDF) on 2026-05-15.
- ^ Page Module:Citation/CS1/styles.css has no content."Repligen 2025 Annual Report" (PDF). Repligen. 2026-02-26. Archived from the original (PDF) on 2026-05-15.
- ^ Page Module:Citation/CS1/styles.css has no content.Nie, Jianqi; Sun, Yang; Feng, Kai; Huang, Lingling; Li, Ye; Bai, Zhonghu (2022-03-18). "The efficient development of a novel recombinant adenovirus zoster vaccine perfusion production process". Vaccine. 40 (13): 2036–2043. doi:10.1016/j.vaccine.2022.02.024. ISSN 1873-2518. PMC 8863426. PMID 35216843.
- ^ Page Module:Citation/CS1/styles.css has no content.Weinberger, Maria E.; Schoch, Luis; Kulozik, Ulrich (2022-10-29). "New technical concept for alternating tangential flow filtration in biotechnological cell separation processes". Biotechnology Progress. 39 (2). doi:10.1002/btpr.3309. ISSN 8756-7938.
- ^ Page Module:Citation/CS1/styles.css has no content."Packing quality, protein binding capacity and separation efficiency of pre-packed columns ranging from 1 mL laboratory to 57 L industrial scale". Journal of Chromatography A. 1591: 79–86. 2019-04-26. doi:10.1016/j.chroma.2019.01.014. ISSN 0021-9673.
- ^ Page Module:Citation/CS1/styles.css has no content.Koch, Jonas; Scheps, Daniel; Gunne, Matthias; Boscheinen, Oliver; Frech, Christian (2023-02-27). "Mechanistic modeling of cation exchange chromatography scale‐up considering packing inhomogeneities". Journal of Separation Science. 46 (9). doi:10.1002/jssc.202300031. ISSN 1615-9306.
- ^ Page Module:Citation/CS1/styles.css has no content.Tona, Robert M.; Shah, Reeti; Middaugh, Kimberly; Steve, Justin; Marques, João; Roszell, Blair R.; Jung, Cindy (2023-06-08). "Process intensification for lentiviral vector manufacturing using tangential flow depth filtration". Molecular Therapy. Methods & Clinical Development. 29: 93–107. doi:10.1016/j.omtm.2023.02.017. ISSN 2329-0501. PMC 10041461. PMID 36994313.
- ^ Page Module:Citation/CS1/styles.css has no content."Time-dependent particle size increase during lipid nanoparticle purification by cross-flow filtration". Journal of Colloid and Interface Science. 694 137663. 2025-09-15. doi:10.1016/j.jcis.2025.137663. ISSN 0021-9797.
- ^ Page Module:Citation/CS1/styles.css has no content."Repligen Launches the CTech™ SoloVPE® PLUS System". investors.repligen.com. Retrieved 2025-10-10.
- ^ Page Module:Citation/CS1/styles.css has no content.Bhangale, Rashmi P.; Ye, Rui; Lindsey, Thomas B.; Wolfe, Leslie S. (2022-02-02). "Application of inline variable pathlength technology for rapid determination of dynamic binding capacity in downstream process development of biopharmaceuticals". Biotechnology Progress. 38 (2) e3236. doi:10.1002/btpr.3236. ISSN 1520-6033. PMC 9285919. PMID 35064963.
- ^ Page Module:Citation/CS1/styles.css has no content."Repligen Acquires Bioprocessing Business of Refine Technology". BioProcess International. Retrieved 2025-10-10.
- ^ Page Module:Citation/CS1/styles.css has no content.Corporation, Repligen (2020-10-27). "Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions". GlobeNewswire News Room. Retrieved 2025-10-10.
Sources
- Page Module:Citation/CS1/styles.css has no content.Forbes (2014). "Alexander Rich". Profiles. Forbes. Archived from the original on 15 March 2014. Retrieved 15 March 2014.
- Page Module:Citation/CS1/styles.css has no content.Gen. Eng. Biotechnol. News (February 15, 2014). "BioMarin Nabs Repligen's HDACi Compound Library". News: Discovery & Development. Gen. Eng. Biotechnol. News (paper). Vol. 34, no. 4. p. 14.
- Page Module:Citation/CS1/styles.css has no content.International New York Times (2014). "Repligen Corporation". Business Day. International New York Times. Company Information. Archived from the original on 15 March 2014. Retrieved 15 March 2014.
- Page Module:Citation/CS1/styles.css has no content.Motley Fool (2014). "Repligen Corp Key Executives RGEN". The Motley Fool. Archived from the original on 15 March 2014. Retrieved 15 March 2014.
- Page Module:Citation/CS1/styles.css has no content."Repligen Corporation, Form 10-K, 2013", SEC Documents, Form 10-K, Repligen, 2014-03-14, Commission File Number 000-14656, retrieved 2026-05-15
{{citation}}: CS1 maint: year (link) - Page Module:Citation/CS1/styles.css has no content.Street Insider (19 September 2011). "Repligen (RGEN) Replaces Board Member Alex Rich with Alfred Goldberg". Street Insider. Archived from the original on 15 March 2014. Retrieved 15 March 2014.
External links
- Business data for Repligen Corporation: Page Template:Hlist/styles.css has no content.
Template:S&P 400 companies Lua error in package.lua at line 80: module 'Module:Authority control/config' not found.
